Table 3.
Characteristics associated with major depressive episode prior to treatment for recent HCV infection (n=160) *
| Characteristic | Depressed, n= 25 |
OR | 95% CI | P | P-Overall | AOR | 95% CI | p |
|---|---|---|---|---|---|---|---|---|
| Age, >34 (vs. ≤34) | 11 (14%) | 0.73 | 0.31–1.72 | 0.472 | – | – | – | – |
| Female sex (vs. male) | 9 (20%) | 1.50 | 0.6–3.7 | 0.385 | – | – | – | – |
| Caucasian ethnicity (vs. other) | 21 (14%) | 0.42 | 0.12–1.46 | 0.173 | – | – | – | – |
| Tertiary education or greater (vs. less than tertiary) | 8 (12%) | 0.66 | 0.27–1.64 | 0.376 | – | – | – | – |
| Full time/part time employment (vs. no employment/other) | 3 (5%) | 0.11 | 0.05–0.61 | 0.007 | – | 0.23 | 0.06–0.82 | 0.023 |
| Rental accommodation (vs. owned) | 5 (13%) | 0.72 | 0.24–2.10 | 0.545 | 0.818 | – | – | – |
| Other types of accommodation (vs. owned) | 3 (14%) | 0.81 | 0.21–3.07 | 0.761 | – | – | – | – |
| Methadone/Buprenorphine therapy- ever (vs. never) | 2 (12%) | 0.70 | 0.15–3.33 | 0.655 | 0.882 | – | – | – |
| Current therapy (vs. never) | 3 (14%) | 0.83 | 0.22–3.09 | 0.782 | – | – | – | – |
| Injecting drug use ever (vs. never) | 22 (18%) | 2.47 | 0.69–8.77 | 0.162 | – | – | – | – |
| Injecting drug use past 6 months (vs. not in past 6 months) | 21 (21%) | 3.95 | 1.29–12.15 | 0.016 | – | – | – | – |
| Injecting drug use past 30 days, yes (vs. not in past month) | 15 (27%) | 3.87 | 1.57–9.58 | 0.003 | – | 3.04 | 1.19–7.72 | 0.019 |
| Social functioning score, 10–16 (vs. 0–9)† | 8 (17%) | 3.37 | 0.84–13.57 | 0.088 | 0.064 | – | – | – |
| ≥17 (vs. 0–9) | 11 (24%) | 5.03 | 1.30–19.37 | 0.019 | – | – | – | – |
| Alcohol- standard drinks/day past month, 3–4 (vs. ≤2)† | 2 (7%) | 0.24 | 0.05–1.15 | 0.074 | – | – | – | – |
| ≥5 (vs. ≤2) | 3 (10%) | 0.36 | 0.09–1.38 | 0.136 | 0.103 | – | – | – |
| Antipsychotic medication (vs. no antipsychotic) | 3 (27%) | 2.16 | 0.53–8.80 | 0.280 | – | – | – | – |
| Antidepressant (SSRI, SNRI,TCA,TeCA) (vs. no antidepressant) | 9 (25%) | 2.25 | 0.90–5.64 | 0.084 | – | – | – | – |
| HCV/HIV co-infection (vs. HCV mono-infection) | 3 (6%) | 0.27 | 0.08–0.96 | 0.040 | – | – | – | – |
*
three participants had missing MINI survey prior to HCV treatment,
†
variables divided to tertiles by distribution
serotonin-norepinephrine reuptake inhibitor (SNRI), selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant (TCA), tetracyclic antidepressant (TeCA)